Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association With Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer

Hormones and Cancer - United States
doi 10.1007/s12672-016-0251-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Aurora Kinase a Stabilizes FOXM1 to Enhance Paclitaxel Resistance in Triple‐negative Breast Cancer

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

DNA Methyltransferase Expression in Triple-Negative Breast Cancer Predicts Sensitivity to Decitabine

Journal of Clinical Investigation
Medicine
2018English

Curcumin Restores Sensitivity to Retinoic Acid in Triple Negative Breast Cancer Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2014English

The Results of a Study of Chemotherapy With Bevacizumab, Oxaliplatin and Paclitaxel in Patients With Metastatic Triple Negative Breast Cancer

Malignant tumours
2017English

Tumor Tissue microRNA Expression in Association With Triple-Negative Breast Cancer Outcomes

Breast Cancer Research and Treatment
Cancer ResearchOncology
2015English

Cisplatin Versus Carboplatin in Combination With Paclitaxel as Neoadjuvant Regimen for Triple Negative Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2017English

Androgen Receptor-Positive, Triple-Negative Breast Cancer

Cancer
Cancer ResearchOncology
2017English

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy